Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice

Neurobiology of Aging

Volumn 33, Issue 2, 2012, Pages 427.e1-427.e14

  Littrell, Ofelia M ^a   Pomerleau, Francois ^a   Huettl, Peter ^a   Surgener, Stewart ^a   McGinty, Jacqueline F ^b   Middaugh, Lawrence D ^b   Granholm, Ann Charlotte ^b   Gerhardt, Greg A ^a   Boger, Heather A ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dopamine; Dopamine transporter; Glial cell line derived neurotrophic factor; In vivo electrochemistry; Movement disorders; Neurodegeneration; Striatum

Indexed keywords

CARBON FIBER; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NOMIFENSINE; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; ELECTROCHEMISTRY; EXON; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; LOCOMOTION; MESENCEPHALON; MICROELECTRODE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SYNAPTOSOME;

EID: 82755161936     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.10.013     Document Type: Article

References (84)

1. Altar C.A., Marshall J.F. Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamine-uptake inhibitors. AnnN Y Acad. Sci 1988, 515:343-354.
2. Backman C.M., Shan L., Zhang Y.J., Hoffer B.J., Leonard S., Troncoso J.C., Vonsatel P., Tomac A.C. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol. Cell. Endocrinol 2006, 252:160-166.
3. Beckstead R.M., Domesick V.B., Nauta W.J. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res 1979, 175:191-217.
4. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M., Evans D.A. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N. Engl. J. Med 1996, 334:71-76.
5. Bentivoglio M., Morelli M. Dopamine Circuits and Receptors. Handbook of Chemical Neuroanatomy 2005, 44-56. Elsevier. S.B. Dunnett, M. Bentivoglio, A. Bjorklund, T. Hokfelt (Eds.).
6. Boger H.A., Granholm A.C., Jin L., Nelson M.E., Page G., McGinty J.F. Striatal gene expression profile of 12 month old GDNF heterozygous mice. Soc. Neurosci. Abstr 2004, 30:725. 17.
7. Boger H.A., Middaugh L.D., Huang P., Zaman V., Smith A.C., Hoffer B.J., Tomac A.C., Granholm A.C. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp. Neurol 2006, 202:336-347.
8. Boger H.A., Middaugh L.D., Patrick K.S., Ramamoorthy S., Denehy E.D., Zhu H., Pacchioni A.M., Granholm A.C., McGinty J.F. Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J. Neurosci 2007, 27:8816-8825.
9. Cass W.A., Gerhardt G.A. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neurosci. Lett 1994, 176:259-263.
10. Cass W.A., Gerhardt G.A. In vivo assessment of dopamine uptake in rat medial prefrontal cortex: comparison with dorsal striatum and nucleus accumbens. J. Neurochem 1995, 65:201-207.
11. Cass W.A., Gerhardt G.A., Mayfield R.D., Curella P., Zahniser N.R. Differences in dopamine clearance and diffusion in rat striatum and nucleus accumbens following systemic cocaine administration. J. Neurochem 1992, 59:259-266.
12. Cass W.A., Manning M.W., Bailey S.L. Restorative effects of GDNF on striatal dopamine release in rats treated with neurotoxic doses of methamphetamine. Ann. N.Y. Acad. Sci 2000, 914:127-136.
13. Cass W.A., Peters L.E., Harned M.E., Seroogy K.B. Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine. Ann. N.Y. Acad. Sci 2006, 1074:272-281.
14. Cass W.A., Zahniser N.R., Flach K.A., Gerhardt G.A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem 1993, 61:2269-2278.
15. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U S A 1988, 85:5274-5278.
16. Fallon J.H., Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol 1978, 180:545-580.
17. Franklin K., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, New York.
18. Friedemann M.N. In vivo Electrochemical Studies of Dopamine Diffusion and Clearance in the Striatum of Young and Aged Fischer-344 Rats. Age 1992, 15:23-28.
19. Friedemann M.N., Gerhardt G.A. Regional effects of aging on dopaminergic function in the Fischer-344 rat. Neurobiol. Aging 1992, 13:325-332.
20. Furman C.A., Chen R., Guptaroy B., Zhang M., Holz R.W., Gnegy M. Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. J. Neurosci 2009, 29:3328-3336.
21. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem 1997, 69:1322-1325.
22. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
23. Gerhardt G.A., Cass W.A., Yi A., Zhang Z., Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J. Neurochem 2002, 80:168-177.
24. Gerhardt G.A., Hoffman A.F. Effects of recording media composition on the responses of Nafion-coated carbon fiber microelectrodes measured using high-speed chronoamperometry. J. Neurosci. Methods 2001, 109:13-21.
25. Gerhardt G.A., Ksir C., Pivik C., Dickinson S.D., Sabeti J., Zahniser N.R. Methodology for coupling local application of dopamine and other chemicals with rapid in vivo electrochemical recordings in freely moving rats. J. Neurosci. Methods 1999, 87:67-76.
26. Gerhardt G.A., Rose G.M., Hoffer B.J. Release of monoamines from striatum of rat and mouse evoked by local application of potassium: evaluation of a new in vivo electrochemical technique. J. Neurochem 1986, 46:842-850.
27. Gerlai R., McNamara A., Choi-Lundberg D.L., Armanini M., Ross J., Powell-Braxton L., Phillips H.S. Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur. J. Neurosci 2001, 14:1153-1163.
28. Ghitza U.E., Zhai H., Wu P., Airavaara M., Shaham Y., Lu L. Role of BDNF and GDNF in drug reward and relapse: A review. Neurosci. Biobehav. Rev 2010, 35:157-171.
29. Glynn G.E., Yamamoto B.K. In vivo neurochemical and anatomical heterogeneity of the dopamine uptake system in the rat caudate putamen. Brain Res 1989, 481:235-241.
30. Granholm A.C., Reyland M., Albeck D., Sanders L., Gerhardt G., Hoernig G., Shen L., Westphal H., Hoffer B. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J. Neurosci 2000, 20:3182-3190.
31. Grondin R., Cass W.A., Zhang Z., Stanford J.A., Gash D.M., Gerhardt G.A. Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J. Neurosci 2003, 23:1974-1980.
32. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elsberry D.D., Klein M.C., Gerhardt G.A., Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002, 125:2191-2201.
33. Halberda J.P., Middaugh L.D., Gard B.E., Jackson B.P. DAD1- and DAD2-like agonist effects on motor activity of C57 mice: differences compared to rats. Synapse 1997, 26:81-92.
34. Hall M.E., Hoffer B.J., Gerhardt G.A. Rapid and Sensitive Determination of Catecholamines in Small Tissue Samples by High Performance Liquid Chromatography Coupled with Dual-Electrode Coulometric Electrochemical Detection. LC GCmag. Sep. Sci 1989, 7:258-265.
35. Hascup K.N., Rutherford E.C., Quintero J.E., Day B.K., Nickell J.R., Pomerleau F., Huettl P., Burmeister J., Gerhardt G.A. Second-by-Second Measures of L-Glutamate and Other Neurotransmitters Using Enzyme-Based Microelectrode Arrays. Electrochemical Methods for Neuroscience, Frontiers in Neuroengineering 2007, 407-450. CRC Press, Boca Raton, FL. A.C. Michael, L.M. Borland (Eds.).
36. Hebert M.A., Gerhardt G.A. Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J. Pharmacol. Exp. Ther 1997, 282:760-768.
37. Hebert M.A., Gerhardt G.A. Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in Fischer 344 rats. Brain Res 1998, 797:42-54.
38. Hebert M.A., Gerhardt G.A. Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: An in vivo electrochemical study. J. Pharmacol. Exp. Ther 1999, 288:879-887.
39. Hebert M.A., Larson G.A., Zahniser N.R., Gerhardt G.A. Age-related reductions in [3H]WIN, p. 35, 428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the fischer 344 rat. J. Pharmacol. Exp. Ther 1999, 288(3):1334-1339.
40. Hebert M.A., Vanhorne C.G., Hoffer B.J., Gerhardt G.A. Functional effects of GDNF in normal rat striatum: Presynaptic studies using in vivo electrochemistry and microdialysis. J. Pharmacol. Exp. Ther 1996, 279:1181-1190.
41. Hefti F., Melamed E., Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 1980, 195:123-137.
42. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.F.H., Gerhardt G.A. Glial-Cell Line-Derived Neurotrophic Factor Reverses Toxin-Induced Injury to Midbrain Dopaminergic-Neurons In-Vivo. Neurosci. Lett 1994, 182:107-111.
43. Hoffman A.F., Gerhardt G.A. In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J. Neurochem 1998, 70:179-189.
44. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol 1987, 45:19-34.
45. Ichitani Y., Okamura H., Nakahara D., Nagatsu I., Ibata Y. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp. Neurol 1994, 130:269-278.
46. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol 1998, 44(suppl 1):S72-S84.
47. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol 1998, 152:259-277.
48. Kluger A., Gianutsos J.G., Golomb J., Ferris S.H., Reisberg B. Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer's disease: diagnostic and differential diagnostic features. Int. Psychogeriatr 1997, 9(suppl 1):307-316.
49. Koob G.F., Stinus L., Le Moal M. Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system. Behav. Brain Res 1981, 3:341-359.
50. Lee C.S., Sauer H., Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72:641-653.
51. Levey A.I., Hersch S.M., Rye D.B., Sunahara R.K., Niznik H.B., Kitt C.A., Price D.L., Maggio R., Brann M.R., Ciliax B.J. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl. Acad. Sci. U S A 1993, 90:8861-8865.
52. Lin L.F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. Gdnf-A Glial-Cell Line Derived Neurotrophic Factor for Midbrain Dopaminergic-Neurons. Science 1993, 260:1130-1132.
53. Mahalik T.J., Hahn W.E., Clayton G.H., Owens G.P. Programmed cell death in developing grafts of fetal substantia nigra. Exp. Neurol 1994, 129:27-36.
54. Marsden C.D. Parkinson's disease. Lancet 1990, 335:948-952.
55. Marshall J.F., Altar C.A. Striatal dopamine uptake and swim performance of the aged rat. Brain Res 1986, 379:112-117.
56. Messer C.J., Eisch A.J., Carlezon W.A., Whisler K., Shen L., Wolf D.H., Westphal H., Collins F., Russell D.S., Nestler E.J. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 2000, 26:247-257.
57. Moore M.W., Klein R.D., Farinas I., Sauer H., Armanini M., Phillips H., Reichardt L.F., Ryan A.M., Carver-Moore K., Rosenthal A. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996, 382:76-79.
58. Nakajima K., Hida H., Shimano Y., Fujimoto I., Hashitani T., Kumazaki M., Sakurai T., Nishino H. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res 2001, 916:76-84.
59. Palmer M.R., Wuerthele S.M., Hoffer B.J. Physical and physiological characteristics of micropressure ejection of drugs from multibarreled pipettes. Neuropharmacology 1980, 19:931-938.
60. Pichel J.G., Shen L., Sheng H.Z., Granholm A.C., Drago J., Grinberg A., Lee E.J., Huang S.P., Saarma M., Hoffer B.J., Sariola H., Westphal H. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996, 382:73-76.
61. Pijnenburg A.J., Honig W.M., Van der Heyden J.A., Van Rossum J.M. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur. J. Pharmacol 1976, 35:45-58.
62. Richards M., Stern Y., Marder K., Cote L., Mayeux R. Relationships between extrapyramidal signs and cognitive function in a community-dwelling cohort of patients with Parkinson's disease and normal elderly individuals. Ann. Neurol 1993, 33:267-274.
63. Sabeti J., Adams C.E., Burmeister J., Gerhardt G.A., Zahniser N.R. Kinetic analysis of striatal clearance of exogenous dopamine recorded by chronoamperometry in freely moving rats. J. Neurosci. Methods 2002, 121:41-52.
64. Salvatore M.F., Gerhardt G.A., Dayton R.D., Klein R.L., Stanford J.A. Bilateral effects of unilateral GDNF administration on dopamine- and GABA-regulating proteins in the rat nigrostriatal system. Exp. Neurol 2009, 219:197-207. Nos.
65. Salvatore M.F., Zhang J.L., Large D.M., Wilson P.E., Gash C.R., Thomas T.C., Haycock J.W., Bing G., Stanford J.A., Gash D.M., Gerhardt G.A. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J. Neurochem 2004, 90:245-254.
66. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
67. Smith A.D., Antion M., Zigmond M.J., Austin M.C. Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRalpha1 and RET mRNAs in the adult rat. Brain Res. Mol. Brain Res 2003, 117:129-138.
68. Sorkina T., Hoover B.R., Zahniser N.R., Sorkin A. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic 2005, 6:157-170.
69. Stanford J.A., Currier T.D., Gerhardt G.A. Acute locomotor effects of fluoxetine, sertraline, and nomifensine in young versus aged Fischer 344 rats. Pharmacol. Biochem. Behav 2002, 71:325-332.
70. Stephens M.L., Quintero J.E., Pomerleau F., Huettl P., Gerhardt G.A. Age-related changes in glutamate release in the CA3 and dentate gyrus of the rat hippocampus. Neurobiol. Aging 2009.
71. Storch A., Ludolph A.C., Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural Transm 2004, 111:1267-1286.
72. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., Humpel C. Glial-Cell Line-Derived Neurotrophic Factor Is Expressed in the Developing But Not Adult Striatum and Stimulates Developing Dopamine Neurons In-Vivo. Exp. Neurol 1993, 124:401-412.
73. Thomas T.C., Kruzich P.J., Joyce B.M., Gash C.R., Suchland K., Surgener S.P., Rutherford E.C., Grandy D.K., Gerhardt G.A., Glaser P.E. Dopamine D4 receptor knockout mice exhibit neurochemical changes consistent with decreased dopamine release. J. Neurosci. Methods 2007, 166:306-314. Nos.
74. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
75. Tuomisto J. Nomifensine and its derivatives as possible tools for studying amine uptake. Eur. J. Pharmacol 1977, 42:101-106.
76. van Horne C.G., Hoffer B.J., Stromberg I., Gerhardt G.A. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. J. Pharmacol. Exp. Ther 1992, 263:1285-1292.
77. Volkow N.D., Fowler J.S., Wang G.J., Logan J., Schlyer D., MacGregor R., Hitzemann R., Wolf A.P. Decreased dopamine transporters with age in health human subjects. Ann. Neurol 1994, 36:237-239.
78. Volkow N.D., Wang G.J., Fowler J.S., Ding Y.S., Gur R.C., Gatley J., Logan J., Moberg P.J., Hitzemann R., Smith G., Pappas N. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann. Neurol 1998, 44:143-147.
79. Wang J.Q., McGinty J.F. Dose-dependent alteration in zif/268 and preprodynorphin mRNA expression induced by amphetamine or methamphetamine in rat forebrain. J. Pharmacol. Exp. Ther 1995, 273:909-917.
80. Willig F., Palacios A., Monmaur P., M'Harzi M., Laurent J., Delacour J. Short-term memory, exploration and locomotor activity in aged rats. Neurobiol. Aging 1987, 8:393-402.
81. Yuan H., Sarre S., Ebinger G., Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods 2005, 144:35-45.
82. Yurek D.M., Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res 2001, 891:228-235.
83. Yurek D.M., Hipkens S.B., Hebert M.A., Gash D.M., Gerhardt G.A. Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats. Brain Res 1998, 791:246-256.
84. Zhang Z., Andersen A., Smith C., Grondin R., Gerhardt G., Gash D. Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. J. Gerontol. A Biol. Sci. Med. Sci 2000, 55. B473-BB80.